EP3429999A1 - Procédé de préparation d'alkylamines - Google Patents
Procédé de préparation d'alkylaminesInfo
- Publication number
- EP3429999A1 EP3429999A1 EP17715229.5A EP17715229A EP3429999A1 EP 3429999 A1 EP3429999 A1 EP 3429999A1 EP 17715229 A EP17715229 A EP 17715229A EP 3429999 A1 EP3429999 A1 EP 3429999A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- heterocycle
- aryl
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Definitions
- the present invention relates to a process for the preparation of alkylamines using carbon monoxide and the use of this process in the manufacture of vitamins, pharmaceuticals, glues, acrylic fibers and synthetic leathers, pesticides, surface, detergents and fertilizers.
- It also relates to a process for producing vitamins, pharmaceuticals, glues, acrylic fibers, synthetic leathers, pesticides, surfactants, detergents and fertilizers, comprising a step of preparing alkylamines by the process according to the invention.
- the present invention further relates to a process for the preparation of labeled alkylamines and their uses.
- Amines are commodities of chemistry. They are especially used as dyes or drugs. Today, methylamines can be synthesized "sustainably" from C0 2 , while alkylamines are synthesized from petrochemical derivatives.
- One of the other main routes of synthesis of alkylamines is the reduction of amides.
- This can be done by hydrogenation of the amides, with, however, limited efficacy and sensitivity to the nature of the amide.
- the hydrogenation can be carried out by hydrosilylation as shown in FIG. 2, or by hydroboration, two techniques which have good yields but a low atomic economy.
- hydrosilylation of amides in the presence of Co 2 CO 8 as a catalyst can have quantitative yields but will be effective only with aromatic amides.
- the number of substituents on the nitrogen atom of the amides and the resulting steric hindrance can influence the reactivity and rate of reduction of the amide.
- the synthetic processes described above involve several steps that require intermediate purifications.
- the labeled alkylamines are of particular interest in many fields, for example in the life sciences (study / elucidation of enzymatic mechanisms, biosynthetic mechanisms, biochemistry, etc. .), environmental sciences (tracing waste, etc.), research (study / elucidation of reaction mechanisms) or research and development of new pharmaceutical and therapeutic products.
- life sciences projecty / elucidation of enzymatic mechanisms, biosynthetic mechanisms, biochemistry, etc. .
- environmental sciences trace, etc.
- research research and development of new pharmaceutical and therapeutic products.
- developing a process as described above for the preparation of labeled alkyl amines meeting the requirements indicated above meets a real need.
- the present invention is specifically intended to meet these needs by providing a process for the preparation of alkylamines of formula (I):
- R 2 and R 3 represent, independently of one another, a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups being optionally substituted; or
- R 3 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups being optionally substituted;
- R 1 , R 2 , R 3 and -CH 2 - optionally include H, C, N, O, F, Si and / or S as defined below:
- H represents a hydrogen atom (H), deuterium (H) or tritium (H);
- C represents a carbon atom (C), a C, C or C isotope;
- N represents a nitrogen atom ( 14 N), an isotope , 5 N;
- O represents an oxygen atom ( 16 0), an isotope i7 0 or , 80;
- F represents a fluorine atom ( I9 F), an 18 F isotope
- o S represents a sulfur atom (S), an isotope S, S or ⁇ S; characterized in that an amine of formula
- - R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups being optionally substituted;
- X represents a halogen atom, trifluoromethylsulphonate (triflate),
- methanesulfonate (mesylate), p-toluenesulfonic acid (tosylate);
- n is an integer selected from 0 and 1; with CO in which C and O are as defined above and a reducing agent selected from H 2 , LiAlH 4 , NaBH 4 , Zn, LiBH 4 ,
- R 4 , R 5 , R 6 , R 7 and R 8 represent, independently of one another, a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a group aryl, a heteroaryl group, a heterocycle, a silyl group, a siloxy group, an amino group, said alkyl, alkenyl or alkynyl groups, aryl, heteroaryl, endocycle, silyl, siloxy and amino being optionally substituted, or
- R and R taken together with the boron atom to which they are attached form an optionally substituted heterocycle; in the presence of a metal catalyst selected from salts and metal complexes, and optionally a promoter.
- the process of the invention has the advantage of enabling CO to be converted to alkylamines with a large choice of amines of formula (II) (primary, secondary, aromatic, aliphatic amines, etc.).
- This process makes it possible to create one or more alkyl chains on the amines of formula (II) and / or to lengthen the alkyl chain (s) already present on the amines of formula (II). ), which, to date, has never been described.
- CO through the presence of reducing agents which provide the reduction of CO under catalytic conditions, is used to alkylate said amines of formula (II).
- Another advantage of the process of the invention is that it allows, when desired, to promote the production of certain types of alkylamines of formula (I) from the amine of formula (II).
- the process of the invention makes it possible to obtain the alkylamines of formula (I) in a limited number of stages (one or two stages) without separation of the intermediate products.
- the preparation of the alkylamines by the process of the invention is monotope ("one-pot” in English), that is to say that the amines of formula (II) ) are converted into alkylamines of formula (I) by undergoing several successive and / or simultaneous reactions in a single reaction mixture (a single reactor for example), thus avoiding the long processes of separation and purification of the intermediate compounds.
- the method of the invention is of great interest because it saves time, cost of production and overall performance.
- amines of formula (II) In order for the process of the invention to lead to the production of alkylamines of formula (I), a judicious and adequate combination of amines of formula (II), reducing agent, catalysts and possibly promoters is essential. . he is in In particular, it is necessary for the amine of formula (II) and the catalyst to be chosen, in particular taking into account their respective steric hindrance, the reducing nature of the reducing agent, the nucleophilic nature of the catalyst and their solubility in the reaction medium.
- the technical challenge to be taken is to couple the functionalization of carbon monoxide (formation of a CN bond) to a chemical reduction step (formation of two CH bonds). ), which is not, a priori, obvious or easy. Indeed, it is not enough that the carbonylation followed by the reduction is done independently but that the carbonylation can take place in the presence of a reducing agent and that the reduction can take place in the presence of CO, and this at the appropriate time and under the same conditions.
- silanes are known to form methane in the presence of iodomethane (promoter) which would deactivate the system, or to form a silylated amine in the presence of an amine as shown in FIG.
- iodomethane promoter
- the inventors have found, quite unexpectedly, that a judicious choice of reagents and operating conditions makes it possible to eliminate the undesirable reactions.
- a judicious choice of reagents and operating conditions makes it possible to perform either a single or a multiple carbonylation and reduction cascade thus leading to the formation of several C-C bonds.
- a “promoter” designates a compound which increases the catalytic power of a catalyst, without itself having intrinsic catalytic power.
- the promoters are themselves inactive.
- the promoters can be of formula RX in which
- R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, the said alkyl, alkenyl, alkynyl, heteroaryl or heterocycle groups being optionally substituted, with the groups alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle as defined within the scope of the present invention;
- X represents a halogen atom chosen from fluorine, chlorine, bromine and iodine atoms; trifluoromethylsulfonate (triflate), methanesulfonate (mesylate) and p-toluenesulfonic acid (tosylate).
- the promoters may also be a quaternary ammonium salt of the formula RgRioRnR ⁇ NX in which - R 9> Rio, Ru, R12 represent, independently of one another, a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups being optionally substituted, with alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups as defined within the scope of the present invention; and
- X represents a halogen atom chosen from fluorine, chlorine, bromine and iodine atoms; trifluoromethylsulfonate (triflate); methanesulfonate (mesylate) and p-toluenesul acid mildew (tosyiate).
- catalyst means a compound capable of modifying, in particular by increasing, the speed of the chemical reaction in which it participates, and which is regenerated at the end of the reaction.
- This definition encompasses both catalysts, that is, compounds that exert their catalytic activity without the need for any modification or conversion, and compounds (also called pre-catalysts) that are introduced into the medium. and converted therein to a catalyst.
- additive denotes a compound capable of improving and increasing the yield and / or the rate of conversion of the amines of formula (II) into alkylamines of formula (I), but which, alone, can not catalyze this conversion.
- the additives may be chosen from amides, preferably aromatic or derived, in particular acetanilide, benzanilide, and N-methylacetanilide; and Lewis acids include AlCl 3, LiCl, LiBF 4j FeCl 3, InCl 3, BiCl 3.
- an "alkyl” group denotes a linear, branched or cyclic, saturated, optionally substituted carbon radical comprising 1 to 12 carbon atoms.
- saturated, linear or branched alkyl there may be mentioned, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, nonyl, decyl, undecyl, dodecanyl and their branched isomers.
- cyclic alkyl there may be mentioned cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloalkyl, bicyclo [2,1,1] hexyl, bicyclo [2,2,1] heptyl radicals.
- the alkyl group may comprise for example 1 to 8 carbon atoms.
- alkenyl or “alkynyl” is meant a linear, branched or cyclic unsaturated carbon radical, optionally substituted, said unsaturated carbon radical comprising 2 to 12 carbon atoms comprising at least one double (alkenyl) or a triple bond (alkynyl) .
- alkenyl or “alkynyl” is meant a linear, branched or cyclic unsaturated carbon radical, optionally substituted, said unsaturated carbon radical comprising 2 to 12 carbon atoms comprising at least one double (alkenyl) or a triple bond (alkynyl) .
- Cyclic alkenyls include, for example, cyclopentenyl, cyclohexenyl.
- the alkenyl and alkynyl groups may comprise for example 2 to 8 carbon atoms.
- the alkyl, alkenyl, alkynyl groups may be optionally substituted by one or more hydroxyl groups; one or more alkoxy groups; one or more halogen atoms selected from fluorine, chlorine, bromine or iodine atoms; one or more nitro groups ( ⁇ N0 2 ); one or more nitrile groups (-CN); one or more aryl groups, with the alkoxy and aryl groups as defined in the context of the present invention.
- aryl generally refers to a cyclic aromatic substituent having from 6 to 20 carbon atoms.
- the aryl group may be mono- or polycyclic.
- the aryl group may be optionally substituted by one or more hydroxyl groups, one or more alkoxy groups, one or more "siloxy" groups, one or more halogen atoms selected from fluorine, chlorine, bromine and iodine atoms, one or more several nitro groups (-NO 2 ), one or more nitrile groups (-CN), one or more alkyl groups, with the alkoxy, alkyl and siloxy groups as defined in the third scope of the present invention.
- the aryl group may comprise, for example, 6 to 10 carbon atoms.
- heteroaryl generally denotes a mono- or polycyclic aromatic substituent having from 5 to 12 members of which at least 2 carbon atoms, and at least one heteroatom selected from nitrogen, oxygen or sulfur.
- furyl benzofuranyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, thiophenyl, benzothiophenyl, pyridyl, quinolinyl, isoquinolinyl, imidazolyl, benzimidazolyl, triazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl groups.
- pyridazinyl pyrimidilyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, 1,1-diphenylhydrazinyl, 1,2-diphenylhydrazinyl, carbazolyl.
- the heteroaryl group may be optionally substituted by one or more hydroxyl groups, one or more alkoxy groups, one or more halogen atoms selected from fluorine atoms, chlorine, bromine and iodine, one or more nitro groups (-N ⁇ 3 ⁇ 4), one or more nitrile groups (-CN), one or more aryl groups, one or more alkyl groups, with the alkyl, alkoxy and aryl groups such as defined in the context of the present invention. It is obvious that the term "heteroaryl” also encompasses mono- or polycyclic aromatic compounds having from 5 to 12 members, of which at least 2 are carbon atoms, and at least one heteroatom chosen from nitrogen, oxygen or sulfur. whose radicals / groups are derived from it.
- alkoxy means an alkyl group, as defined above, bonded through an oxygen atom (-O-alkyl).
- heterocycle or heterocyclic generally refers to a saturated or unsaturated mono- or polycyclic 5 to 12-membered substituent containing from 1 to 4 heteroatoms selected independently of one another from nitrogen, oxygen, boron and sulfur.
- borolane borole, borinane, 9-borabicyclo [3.3.1] nonane (9-BBN), 1,3,2-benzodioxaborole (catecholborane or catBH), pinacholborane (pinBH) ; morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrimidinyl, tetrahydroisoquinolinyl, benzazepinyl, triazolyl, pyrazo
- the heterocycle may be optionally substituted by one or more hydroxyl groups, one or more alkoxy groups, one or more aryl groups, one or more halogen atoms selected from fluorine, chlorine, bromine and iodine atoms, one or more groups. nitro (-NO 2 ), one or more nitrile groups (-CN), one or more alkyl groups, with the alkyl, alkoxy and aryl groups as defined within the scope of the present invention.
- heterocycle or heterocyclic also encompasses saturated or unsaturated 5 to 12 membered mono- or polycyclic compounds containing from 1 to 4 heteroatoms chosen independently of each other, from 1 nitrogen, oxygen, boron and sulfur, from which the above-mentioned radicals / groups derive therefrom.
- atom of "halogen” is meant an atom chosen from fluorine, chlorine, bromine and iodine atoms.
- sil means a group of the formula [-Si (Y) 3] wherein each Y, independently of one another, is selected from hydrogen; one or more halogen atoms selected from fluorine, chlorine, bromine or iodine atoms; a or more alkyl groups; one or more alkoxy groups; one or more siloxy groups; one or more aryl groups; with the alkyl, alkoxy and aryl groups as defined in the context of the present invention, for example, trimethylsilyl (TMS), triethylsilyl ((CH 3 CH 2 ) 3 Si- or TES) may be mentioned; ,? -?
- siloxy group is meant a silyl group, as defined above, linked by an oxygen atom (-O-Si (Y) 3 ) with Y as defined above.
- Y oxygen atom
- trimethylsiloxy-OSi (CH 3 ) 3 triethylsilyoxy-OSi (CH 2 CH 3 ) 3
- tert-butyldiphenylsiloxy-OSi (iBuPh 2 ) 3 methylsiloxy (-OSi ( H) 2 (CH 3 ), dimethylsiloxy (- OSi (H) (CH 3 ) 2 ), ethylsiloxy (-OSi (H) 2 (C 2 3 ⁇ 4), diethylsiloxy (-OSi (H) (C 2 H) 5 ) z ), tetramethyldisiloxane (TMDS or O (Si (Me) 2 H) 2 )
- the siloxy group also includes polymeric silox
- polymethylhydrosiloxane (PMHS), polydimethylsiloxane, poly (dimethylsiloxane-C0-diphenylsiloxane). It is quite obvious that the term "siloxy” also encompasses the compounds of which the above-mentioned radicals / groups derive therefrom.
- amino group is meant a group of formula -NR 13 R 14 , in which: R B and R 14 represent, independently of one another, a hydrogen atom, an alkyl group, an alkenyl group , an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, a silyl group, a siloxy group, with alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, silyl, siloxy, as defined in the context of the present invention; or
- R 13 and R 14 taken together with the nitrogen atom to which they are attached form a heterocycle optionally substituted with one or more hydroxyl groups; one or more alkyl groups; one or more alkoxy groups; one or more halogen atoms selected from fluorine, chlorine, bromine and iodine atoms; one or more nitro groups (-NO 2 ); one or more nitrile groups (-CN); one or more aryl groups; with the alkyl, alkoxy and aryl groups as defined in the context of the present invention. It is obvious that the term "amino" also encompasses compounds whose radicals / groups above derive from it.
- radicals / groups produced in the context of the present invention extend and also include the compounds of which said radicals / groups derive therefrom.
- the substituents, radicals and groups defined above may optionally contain deuterium ( 2 H), tritium ( 3 H), n C, 13 C, 14 C, 15 N, 17 0, 18 0, the i & F, 3 S, 34 S and / or 36 S.
- the compounds of formula (I), (II) contain at least one radiolabel / radiotracer or an isotope, they may also be designated by the formulas (F), ( ⁇ ) and ( ⁇ ).
- a R 1 , R 2 and R 3 represent, independently of one another, a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups; being optionally substituted;
- ⁇ q, q '5 q are integers selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
- BR 1 , R 2 and R 3 represent, independently of one another, a hydrogen atom; an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof; an optionally substituted aryl group selected from benzyl, phenyl, o-toluyl, m-toluyl, p-nitrophenyl, o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl, o-methoxybenzyl, p-methoxybenzyl, m-methoxybenzyl, o-methylbenzyl, p-methylbenzyl and m-methylbenzyl.
- the presence of a promoter and / or an additive may be advantageous.
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycle
- R 3 represents a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups being optionally substituted;
- R 2 taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycle selected from morpholine, piperidine, piperazine, pyrrolidine and tetrahydroisoquinoline, indoline and isoindoline, and
- R represents a hydrogen atom; an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof; an optionally substituted aryl group selected from benzyl, phenyl, o-toluyl, m-toluyl, p-nitrophenyl, o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl, o-methoxybenzyl, p-methoxybenzyl, p-methoxybenzyl, m-methoxybenzyl, o-methylbenzyl, p-methylbenzyl and m-methylbenzyl.
- the presence of a promoter and / or an additive may be advantageous.
- n R, R and R represent, independently of one another, a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups being optionally substituted; ;
- ⁇ R is a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle being optionally substituted;
- B l > l are es * integers selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
- ⁇ X represents a halogen atom, trifluoromethylsulfonate (triflate) , methanesulfonate (mesylate), p-toluenesulfonic acid (tosylate).
- R 1, R 2 and R 3 represent, independently of one another, a hydrogen atom; an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof; optionally substituted aryl selected from benzyl, phenyl, o-toluyl, m-toluyl, p-nitrophenyl, o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl, o-methoxybenzyl, p-methoxybenzyl, m-tolyl methoxybenzyl, o-methylbenzyl, p-methylbenzyl and m-methylbenzyl;
- R represents a hydrogen atom; an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof, an optionally substituted aryl group selected from o-methoxybenzyl, p-methoxybenzyl, m-methoxybenzyl, o- methylbenzyl, p-methylbenzyl and m-methylbenzyl.
- the method of the invention does not require the presence of a promoter. However, the use of an additive can be advantageous.
- R represents a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups being optionally substituted;
- R represents a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups being optionally substituted;
- ⁇ m, m 'and m "are are integers chosen from 0 and 1
- ⁇ q q ⁇ q is integers selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
- B X represents a halogen atom, trifluoromethylsulfonate (triflate), methanesulfonate (mesylate), p-toluenesulfonic acid (tosylate).
- R ! and R 2 taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycle selected from morpholine, piperidine, piperazine, pyrrolidine and tetrahydroisoquinoline, indoline and isoindoline, and
- R 3 represents a hydrogen atom; an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof; an optionally substituted aryl group selected from benzyl, phenyl, o- toluyl, m-toluyl, p-nitrophenyl, o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl, o-methoxybenzyl, p-methoxybenzyl, m-methoxybenzyl, o-methylbenzyl, p-methylbenzyl and the like.
- f i R represents a hydrogen atom, an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, optionally substituted aryl group selected from benzyl, o-methoxybenzyl, p-methoxybenzyl , m-methoxybenzyl, o-methylbenzyl, p-methylbenzyl and m-methylbenzyl, and their branched isomers.
- X represents a halogen atom selected from fluorine, chlorine, bromine and iodine.
- the method of the invention does not require the presence of a promoter.
- the use of an additive can be advantageous.
- the values of m, m ', m ", q, q' and q" in the alkylamines of formula (I) are preferably chosen in such a way that :
- the reducing agent is, in particular, chosen from H 2 , a silane of formula (III)
- R 4 , R 5 , R 6 , R 7 and R 8 represent, independently of one another, a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a group aryl, a heteroaryl group, a heterocycle, a silyl group, a siloxy group, an amino group, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, siiyl, siloxy and amino groups being optionally substituted, or
- R 7 and R 8 taken together with the boron atom to which they are attached form an optionally substituted heterocycle.
- the reducing agent is chosen from H 2 , a silane of formula (III) and a borane of formula (IV) in which
- R 4, R s, R 6, R 7 and R 8 represent, independently of one another, a hydrogen atom; an alkyl group selected, for example, from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and their branched isomers, cyclohexyl; an alkoxy group selected, for example, from methoxy and ethoxy; an optionally substituted aryl group selected, for example, from benzyl and phenyl; a siloxy group chosen, for example, trimethyl siloxy-OSi (CH 3 ) 3, triethylsiloxy-OSi (CH 2 CH 3 ) 3 , tert-butyldiphenylsiloxy-OSi (fBuPh 2 ) 3 , methylsiloxy (-OSi ( H) 2 (CH 3 ), dimethyl siloxy (-OSi (H) (CH 3 ) 2 ), ethylsiloxy
- R 7 and R 8 taken together with the boron atom to which they are attached form a heterocycle, said heterocycle being selected from catecholborane (catBH), pinacolborane (pinBH) or 9-borabicyclo [3.3.1] nonane (9-BBN).
- CatBH catecholborane
- pinBH pinacolborane
- 9-BBN 9-borabicyclo [3.3.1] nonane
- the reducing agent is chosen from 3 ⁇ 4 and a silane of formula (III) in which
- R 4 , R 5 , R 6 , R 7 and R 8 represent, independently of one another, a hydrogen atom; an alkyl group selected, for example, from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and their branched isomers, cyclohexyl; an alkoxy group selected, for example, from methoxy and ethoxy, an optionally substituted aryl group selected, for example, from benzyl and phenyl, a siloxy group selected from dimethyl siloxy (-OSi (H) (CH 3 ) 2 ), ethylsiloxy (-OSi (H) 2 (C 2 H 5 ), polymethylhydrosiloxane (PMHS).
- an alkyl group selected, for example, from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and their branched is
- a reducing agent By way of example of a reducing agent, mention may be made of H 2 (C 6 H 5 ) SiH 3 , (C 6 H 5 ) 2 SiH 2 , (CH 3 CH 2 ) 3 SiH, (EtO) 3 SiH , dimethylsiloxane, polymethylhydrosiloxane (PMHS), tetramethyldisiloxane (TMDS or O (Si (Me) 2 H) 2 ).
- PMHS polymethylhydrosiloxane
- TMDS tetramethyldisiloxane
- O Si (Me) 2 H) 2
- the promoter may be of formula RX, with R representing a hydrogen atom, an alkyl group, a heteroaryl group, an aryl group, a heterocycle, said alkyl, aryl, heteroaryl, heterocycle groups being optionally substituted; and X representing a halogen atom, trifluoromethylsulfonate (triflate), methanesulfonate (mesylate), p-toluenesulfonic acid (tosylate).
- the promoter may also be a quaternary ammonium salt of formula R9R10R. Î 1R12 wherein
- J ⁇ ⁇ independently of one another, a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, said alkyl, alkenyl, alkynyl aryl, heteroaryl, heterocycle being optionally substituted, with alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle groups as defined within the scope of the present invention; and
- X represents a halogen atom chosen from fluorine, chlorine, bromine and iodine atoms; trifluoromethylsulfonate (triflate); methanesulfonate (mesylate) and p-toluenesulfonic acid (tosylate).
- the promoter is advantageously of formula RX.
- the promoter is of the formula RX with R representing an alkyl group selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and branched isomers thereof; an optionally substituted aryl group selected from benzyl, o-methoxybenzyl, p-methoxybenzyl, m-methoxybenzyl, o-methylbenzyl, p-methylbenzyl and m-methylbenzyl; and X represents a halogen atom selected from fluorine, chlorine, bromine and iodine.
- iodomethane iodomethane
- iodoethane iodopropane
- iodomethane iodomethane
- the catalyst may be a metal catalyst chosen from salts and metal complexes.
- the metal can then be a transition metal selected from chromium, tungsten, manganese, rhenium, silver, ruthenium, rhodium, cobalt, iron, nickel, copper, iridium, nickel, osmium, molybdenum, gold, platinum and palladium.
- the metal catalyst is a metal salt
- the anions which can form salts with the aforementioned transition metals are chloride (Cl - ), sulphate (SO 4 - 2 ),
- S sulfide
- NO 3 nitrate
- O oxide
- OH hydroxide
- the catalyst may also be a metal complex.
- metal complex an organometallic or inorganic coordination compound in which a metal ion is bonded to an organic or inorganic ligand.
- An organometallic or inorganic complex may be obtained by mixing a metal salt with a ligand, which ligand binds to the metal by phosphorus, carbon, nitrogen, oxygen, hydrogen or silicon atoms, for example.
- the ligands that can be bonded to the aforementioned transition metals can be chosen from:
- nitrogenous bases such as, for example, secondary or tertiary amines chosen from trimethylamine, triethylamine, piperidine, 4-dimethylaminopyridine (DMAP), 1,4-diazabicyclo [2.2.2] octane (DABCO), proline, phenylalanine, thiazolium salt, N-diisopropylethylamine (DIPEA or DIEA), bipyridyl (bipy), terpyridine (terpy); phenantroline (phen), ethylenediamine, N, N, N ', N'-tetramethyl-ethylenediamine (TMEDA), quinoline and pyridine;
- DMAP dimethylaminopyridine
- DIEA 1,4-diazabicyclo [2.2.2] octane
- proline phenylalanine, thiazolium salt
- DIPEA or DIEA N-diisopropylethyl
- phosphorus bases such as, for example, alkyls and aryl phosphines chosen from triphenylphosphine, 2,2'-bis (diphenylphosphino) -1,1'-binaphthyl ( ⁇ ⁇ ), triisopropylphosphine, tris [2-diphenylphosphino); ethyl] phosphine (PP 3 ), tricyclohexylphosphine, 1,2-bis-diphenylphosphinoethane (dppe), 1,2-bis (diphenylphosphino) ethane (dppb); alkyl and aryl phosphonates selected from diphenylphosphate, triphenylphosphate (TPP), tri (isopropylphenyl) phosphate (TIPP), cresyldiphenyl phosphate (CDP), tricresylphosphate (TCP); alkyl and aryl phosphates selected from di-n-but
- oxygenated bases such as, for example, acetate (OAc), acetylacetonate, methanolate, ethanolate, benzoyl peroxide;
- silylated ligands for example alkylsilyls or arylsilyls chosen from triphenylsilyl, diphenylhydrosilyl, trimethylsilyl, dimethylhydrosilyl, triethylsilyl and triethoxysilyl; carbon-containing ligands chosen from, for example, CO, CN " , and N-heterocyclic carbenes derived from an imidazolium salt chosen from 1,3-bis (2,6-diisopropylphenyl) -1H-imidazol salts; 3-ium (IPr), 1,3-bis (2,6-diisopropylphenyl) -4,5-dihydro-1H-imidazol-3-ium, 1,3-bis (2,4,6-trimethylphenyl) 1H-imidazol-3-ium (IMes), 1,3-bis (2,4,6-trimethylphenyl) -4,5-dihydro-1H-imidazol-3
- the metal complex may optionally comprise a counterion chosen from, for example, sodium (Na + ), potassium (K + ), ammonium (H 4 + ).
- a counterion chosen from, for example, sodium (Na + ), potassium (K + ), ammonium (H 4 + ).
- the metal complex may be bimetallic.
- certain ligands may be "in bridging", that is to say, simultaneously bonded to two metal centers, for example CChCOg, Fe 2 C09 or Fe 3 C0 12 .
- metal complexes include, Co 2 CO g, [Fe (CO) 5], [Ir (CO) (Cl) (PPh 3) 2] [Cr (CO) 3 ⁇ 6 -C 6 3 ⁇ 4)], Fe (acac) 3 , Cu (OAc) 2 (3 ⁇ 4O), NaCoC0 4 , MoCo 6 , FeC0 5 , and Co 2 COs optionally in the presence of bipyndyl (bipy), terpyridine (terpy) or phenantroline (phen).
- the ligands used are N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- carbon-containing ligands selected from, for example, CO, CN " , 1,3-bis (2,4,6-trimethylphenyl) -1H-imidazol-3-ium (IMes) and 1,3-bis (2,6-bis); diisopropylphenyl) -1H-imidazol-3-ium (IPr); nitrogenous bases such as, for example, secondary or tertiary amines selected from bipyridyl (bipy), phenantroline (phen), terpiridine (terpy), quinoline.
- IMes 1,3-bis (2,4,6-trimethylphenyl) -1H-imidazol-3-ium
- IPr diisopropylphenyl) -1H-imidazol-3-ium
- nitrogenous bases such as, for example, secondary or tertiary amines selected from bipyridyl (bipy), phenantroline (phen), terpiridine (terpy), quinoline.
- the metal is selected from cobalt, iron and molybdenum.
- the metal complexes preferentially used are NaCoCO, *, MoC0 6 , FeCOs, Fe 3 COi 2 and Co 2 CO 8 optionally in the presence of bipyridyl (bipy), terpyridine (terpy) or phenantroline (phen) to form [(bipy) 3 Co ] 2+ ([CoCC4] ⁇ ) 2 , [(terpy) 2 Co] 2+ [CoCO4] - J (phen) 3 Co] 2+ [CoCO4] -.
- the catalyst is preferably a metal complex.
- the catalysts may, where appropriate, be immobilized on heterogeneous supports, for example, in order to ensure easy separation of said catalyst and / or its recycling.
- Said heterogeneous supports may be chosen from supports based on silica gel or on plastic polymers such as, for example, polystyrene; carbon supports selected from carbon nanotubes; silica carbide; alumina; or magnesium chloride (MgCl 2 ).
- the process of the invention may furthermore take place in the presence of an additive.
- the additives may be selected from especially aromatic amides such as, for example, acetanilide, benzanilide, and N-methylacetanilide; Lewis acids such as, for example, AlCl 3 , LiCl, L 1 BF 4 , FeCl 3 , InCl 3 , BCl 3 .
- the reaction can take place under CO pressure.
- the pressure of the CO can then be between 1 and 200 bar, preferably between 1 and 100, more preferably between 1 and 60 bar inclusive.
- a mixture of CO and H 2 can also be used.
- the pressure of 3 ⁇ 4 is independent of that of CO.
- the CO pressure can then be between 1 and 200 bar, preferably between 1 and 100, more preferably between 1 and 60 bar inclusive, and the pressure of H 2 can be between 1 and 100 bar, preferably between let 50 bars, more preferably between 5 and 30 bars, limits included.
- a pressure of CO is preferred to a mixture of pressures of CO and H 2 .
- the reaction may be carried out at a temperature of between 25 and 300 ° C., preferably between 50 and 250 ° C., more preferably between 80 and 200 ° C., inclusive.
- the reaction time depends on the conversion rate of the amine of formula (II).
- the optimal reaction time corresponds to the complete conversion of the amine of formula (II).
- the reaction time is between 1 hour and 72 hours, preferably preferably between 3 and 24 hours, limits included.
- the process of the invention in particular the reaction between the different reactants, may take place in a mixture of at least two solvents chosen from:
- ethers chosen from diethyl ether, THF, dioxane and diglyme;
- NMP N-methyl-2-pyrrolidone
- DMF N-dimethylformamide
- hydrocarbons chosen from benzene, toluene, pentane and hexane;
- the nitrogenous solvents chosen from pyridine and acetonitrile
- sulfoxides such as dimethyl sulphoxide
- alkyl halides selected from chloroform and methylene chloride
- aryl halides chosen from chlorobenzene and dichlorobenzene.
- the concentration of the amine of formula (II) in the reaction medium is between 0.01 and 10 M, preferably between 0.1 and 5 M, more preferably between 0, 1 and 2 M, inclusive limits. .
- the amount of catalyst is from 0.00001 to 1 molar equivalent, preferably from 0.0001 to 0.9 molar equivalents, more preferably from 0.0001 to 0.2 molar equivalents, even more preferentially from 0.001 to 0.1 equivalents. molar, inclusive limits, with respect to Famine of formula (II).
- the amount of promoter is between 0.00001 and 1 molar equivalent, preferably between 0.01 and 0.9 equivalent. molar, more preferably between 0.1 and 0.4 molar equivalents, inclusive limits, relative to the amine of formula (II).
- the amount of additive is between 0.00001 and 0.5 molar equivalents, preferably between 0.01 and 0.9 molar equivalents, more preferably between 0.1 and 0.4. molar equivalent, inclusive limits, with respect to the amine of formula (II).
- the various reagents used in the process of the invention are, in general, commercial compounds or compounds which can be prepared by methods known to those skilled in the art.
- the process of the invention also makes it possible to prepare marked alkylamines of formula (I).
- the labeled alkylamines correspond to the alkylamines of formula (I) comprising at least one radiolabel / radiotracer or a selected isotope.
- Isotopes mean, for the same element, two atoms having the same number of protons (and electrons) but a different number of neutrons. Having the same number of electrons and protons, the chemical properties of the isotopes of the same element are almost identical. There may, however, be slight variations in the rate of a chemical reaction when one of the atoms of a reagent is replaced by one of its isotopes. On the other hand, as the nucleus does not have the same number of neutrons, the mass of the atoms varies which can make the atom unstable: that is why they can be radioactive. These are radioisotopes. In the context of the invention, the term “isotopes" may also include "radioisotopes".
- Radiolabeling is the act of associating with a given molecule or compound an isotope that will make it possible to follow the evolution or / and the fixation of the molecules, for example, in an organ.
- the radiotracer is the radioactive element (s) present within a molecule to follow the path of this substance, for example, in an organ.
- This method can thus provide access to alkylamines marked n C, 13 C,! 4 C, I5 N,! 7 0, 3 ⁇ 48 F 2 Si 5 30 Si, 33 S, 34 S, 36 S, 2 H (D ) and / or 3 H (T).
- alkylamines of formula (I) The conditions of temperature, reaction time, solvent, as well as the amounts of reagents and catalysts used in the preparation process labeled alkylamines are those previously described in the process of preparing alkylamines of formula (I).
- the ability to form the labeled alkylamines can be ensured by the availability of corresponding labeled reagents, e.g., by amino RR NH enriched N are accessed from the ammonium chloride enriched 15 N: [i5 NH 4] [Cl ] (Yong-Joo Kim, Max P. Bernstein, Angela S. Galiano Roth, Floyd E. Romesberg, Paul G. Williard, David J. Fuller, Aidan T. Harrison, and David B. Colum, J. Org, Chem. 1991, 56, pp. 4435-4439);
- R R NH amines with labeled R and / or R are prepared by the synthetic routes detailed by U. Pleiss, R. Voges, "Synthesis and Applications of Isotopically Labeled Compounds, Volume 7", Wiley-VCH, 2001; and R. Voges, J. R. Heys, T. Moenius, "Preparation of Compounds Labeled with Tritium and Carbon-14", Wiley-VCH: Chippenham (UK), 2009);
- the iodoalkanes for example 13 CH 3 I, 13 CH 3 13 CH 2 I and 14 CH 3 I, are respectively commercial and easily synthesizable from Ba 14 CO 3 .
- the labeled CO C n, C i4 I3 or C is used in the process for preparing marked alkylamines of formula ( ⁇ ).
- Molecules labeled 14 C have contributed to many advances in life sciences (enzymatic mechanisms, bio synthetic mechanisms, biochemistry), environmental sciences (tracing of waste), research (elucidation of reaction mechanisms), diagnosis, research and development of new pharmaceutical and therapeutic products.
- the labeled molecules l C indeed, have an advantage for metabolic studies because C is easily detectable and quantifiable in vitro medium as in vivo.
- the main source of 14 C is 14 CO which is obtained by acidification of barium carbonate Ba 14 C0 3 .
- the development of methods for synthesizing basic molecules used for the preparation of drugs is essential to produce 14 C labeled active ingredients whose metabolism can thus be determined (, Voges, J., R. Heys, T. Moenius, "Preparation of Compounds Labeled with Tritium and Carbon-14" Wiley-VCH: Chippenham (UK), 2009).
- the subject of the invention is also the use of the process for the preparation of alkylamines of formula (I) according to the invention, in the manufacture of vitamins, pharmaceutical products, glues, acrylic fibers and synthetic leathers, pesticides, surfactants, detergents and fertilizers.
- the invention also relates to the use of the method for preparing alkylamines of formula (1) labeled according to the invention, in the manufacture of radiotracers and radiolabel.
- radiotracers and radiolabels include 6-bromo-7- [ n C] methylpurine and 6-bromo-7- [ 14 C] methylpurine, [N- [ 1 C] methyl] -2- (4 , - (methylammo) phenyl) -6-hydroxybenzothiazole (also called [ 1 C] PIB), the structures of which are represented below:
- the subject of the invention is also a process for producing vitamins, pharmaceutical products, glues, acrylic fibers, synthetic leathers, pesticides, fertilizers, surfactants and detergents characterized in that it comprises (i) a step of preparing alkylamines of formula (I) by the process according to the invention, and optionally (ii) a hydrolysis step or an acidification step, to form, for example, the corresponding hydrochloride, borohydrate, hydrofluoride or iodohydrate. After the hydrolysis, optionally distillation or concentration in vacuo may be necessary.
- the subject of the invention is also a process for producing tracers and radiotracers, characterized in that it comprises (i) a step for preparing alkylamines of formula (I) labeled by the process according to the invention and optionally (ii) a hydrolysis step or an acidification step, to form, for example, the corresponding hydrochloride, borohydrate, hydrofluoride or iodohydrate. After the hydrolysis, optionally distillation or concentration in vacuo may be necessary.
- the process according to the invention leads to the formation of alkylamines whose length of alkyl chains present may be different.
- the process of the invention makes it possible to create and / or extend the alkyl chain (s) already present on the amines of formula (II) independently and in a controlled manner.
- the by-products which may be formed during the process of the invention generally correspond to the amides resulting from the carbonylation of the corresponding alkylamines formed.
- a simple filtration may make it possible to recover the optionally supported catalyst and to eliminate some of the by-products that may be formed.
- the amides can be separated by filtration on silica, recycled and reused in the process of the invention.
- Figure 1 shows the alkylation of amines using alcohols or haloalkanes via the Fischer-Tropsch process.
- Figure 2 shows the reduction of araides to amines by hydrosilylation of amides in the presence of Co 2 CO 8 as a catalyst.
- Figure 3 shows the adverse reactions that may occur when the carbonylation reaction occurs in the presence of a reducing agent and a promoter and that the reduction occurs in the presence of CO.
- silanes reducing agent
- iodomethane promoter
- the reagents used in particular the amine of formula (II), the catalyst, the promoter and the reducing agent are commercial products or can be synthesized following the procedures described in the literature.
- the synthesis of NaCoC04 is described in F. W. Edgell, J. Lyford, Inorg. Chem., 1970, 1932 the synthesis of N-methyl-1,2,3,4-tetrahydrosioquinoline in C. Casagrande, A. Galli, R. Ferrini, G. Miragoli, Farmaco, Ediette Scientifica, 1972, 445.
- the remaining used products are purchased from Sigma-Aldrich.
- the process for the preparation of alkylamines of formula (I) can be carried out in a single step and in a single reaction mixture and in the same autoclave (one step one-pot) according to the following experimental protocol.
- An autoclave is loaded in a glove box with the catalyst (between 0.001 and 0.1 molar equivalents), the amine of formula (II) (1 molar equivalent), the promoter (between 0.1 and 1 molar equivalent), 1 reducing agent (between 1 and 6 molar equivalents), optionally an additive and the solvent.
- the amine concentration of formula (II) in the reaction medium is between 0.05 M and 0.3 M, the order of addition is not important.
- the autoclave is sealed and then purged several times (4 times) with 10 bar of CO and the temperature is raised to between 50 and 200 ° C. in 35 minutes.
- the CO pressure is maintained between 1 and 100 bar.
- the reaction time is 1 to 24 hours.
- the autoclave is cooled to room temperature (20 ⁇ 5 ° C).
- the crude reaction product is filtered through Celite.
- the volatile compounds are removed under reduced pressure and the reaction mixture containing the various alkylamines is purified by chromatography on silica gel using ethyl acetate / n-pentane as eluent to obtain the analytically pure alkylamines.
- Example 2 The same procedure as that of Example 1 is followed. In this example, different reducing agents have been tested.
- the amount of reducer and the type of reducer are crucial factors since the performance depends on it. Yields are determined by GC / MS. The yields of alkylamines have not been optimized but are encouraging. The by-products obtained are the corresponding amides which come from the carbonylation of the corresponding alklyamines. These amides can be recycled and serve as starting products.
- the process for the preparation of alkylamines of formula (I) can be carried out in two stages and in a single reaction mixture (two steps one-pot) according to the following experimental protocol.
- An autoclave is loaded glove box with the catalyst (between 0.001 and 0.1 molar equivalent), the amine of formula (II) (1 equivalent), the promoter (between 0.3 and 1 molar equivalent) and the solvent.
- the concentration of amine of formula (II) in the reaction medium is between 0.01 M and 0.3 M. The order of addition is not important.
- the autoclave is sealed and then purged several times (4 times) with 10 bar of CO and the temperature is raised to between 150 and 200 ° C. in 35 minutes.
- the CO pressure is maintained between 1 and 100 bar.
- the reaction time is 1 to 24 hours.
- the autoclave is then purged with 4 times 5 bar of argon and then the reducing agent (between 1 and 6 molar equivalents) is introduced.
- the autoclave is then heated at 50 to 200 ° C for 1 to 10 hours.
- the autoclave is cooled to room temperature (20 ⁇ 5 ° C).
- the crude reaction product is filtered through Celite.
- the volatile compounds are removed under reduced pressure and the reaction mixture containing the various alkylamines is purified by chromatography on silica gel using ethyl acetate / n-pentane as eluent to obtain the analytically pure alkylamines.
- a Wilmad NMR tube (or an autoclave) is loaded in a glove box with the catalyst (between 0.001 and 0.1 molar equivalent), the amine of formula (II) (1 equivalent), the promoter (between 0.3 and 1 molar equivalent) and the solvent.
- the concentration of amine is between 0.01 M and 0.3 M.
- An additive (between 0.05 and 1 molar equivalent) can be added to promote the reaction.
- This additive can be an amide or a Lewis acid as described above.
- the tube is sealed and then purged several times (2 times) with 10 bar of CO.
- the tube is then pressurized to a CO pressure between 1 and 30 bar.
- the tube is then heated to between 50 ° C and 150 ° C.
- the autoclave is cooled to room temperature (20 ⁇ 5 ° C).
- the crude reaction product is filtered through Celite.
- the volatile compounds are removed under reduced pressure and the reaction mixture containing the alkylamines is purified by silica gel chromatography using ethyl acetate / n-pentane as eluent to obtain the analytically pure alkylamines.
- Yields are determined by GC / MS. The yields of alkylamines have not been optimized but are encouraging. The possible by-products obtained are the corresponding amides which come from the carbonylation of the corresponding alklyamines. These amides can be recycled and serve as starting products.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1652230A FR3048968B1 (fr) | 2016-03-16 | 2016-03-16 | Procede de preparation d'alkylamines |
| PCT/FR2017/050570 WO2017158275A1 (fr) | 2016-03-16 | 2017-03-14 | Procédé de préparation d'alkylamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3429999A1 true EP3429999A1 (fr) | 2019-01-23 |
Family
ID=56008750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17715229.5A Withdrawn EP3429999A1 (fr) | 2016-03-16 | 2017-03-14 | Procédé de préparation d'alkylamines |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11084777B2 (fr) |
| EP (1) | EP3429999A1 (fr) |
| FR (1) | FR3048968B1 (fr) |
| WO (1) | WO2017158275A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283725B2 (en) | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| EP3866794B1 (fr) | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine |
| EP3976101A4 (fr) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| CN116854596A (zh) * | 2022-03-28 | 2023-10-10 | 丰益高分子材料(连云港)有限公司 | 一种降低脂肪伯胺中酰胺含量的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2821397B1 (fr) * | 2013-07-05 | 2016-11-30 | Rheinisch-Westfälisch-Technische Hochschule Aachen | Procédé pour la méthylation de composés organiques contenant de l'azote |
-
2016
- 2016-03-16 FR FR1652230A patent/FR3048968B1/fr not_active Expired - Fee Related
-
2017
- 2017-03-14 WO PCT/FR2017/050570 patent/WO2017158275A1/fr not_active Ceased
- 2017-03-14 US US16/083,916 patent/US11084777B2/en not_active Expired - Fee Related
- 2017-03-14 EP EP17715229.5A patent/EP3429999A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR3048968B1 (fr) | 2018-03-02 |
| US20190084917A1 (en) | 2019-03-21 |
| WO2017158275A1 (fr) | 2017-09-21 |
| US11084777B2 (en) | 2021-08-10 |
| FR3048968A1 (fr) | 2017-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3429999A1 (fr) | Procédé de préparation d'alkylamines | |
| EP2861556B1 (fr) | Procédé de préparation d'amines méthylées | |
| EP2694469B1 (fr) | Procede de preparation de composes formamides | |
| EP0748326B1 (fr) | Diphosphines optiquement actives, leur preparation par dedoublement du melange racemique | |
| EP1392708B1 (fr) | Procede de preparation de catalyseurs metalliques a base de carbenes, pour l'hydrosilylation de composes insatures et catalyseurs de ce type | |
| EP2855427B1 (fr) | Procédé de préparation de composés azotés | |
| EP2981539B1 (fr) | Procédé de préparation de composes oxyboranes | |
| EP2906532A1 (fr) | Procede de preparation de formamidines | |
| EP3374364B1 (fr) | Utilisation de formiates de bore pour la reduction de fonctions organiques insaturees | |
| EP3374363A1 (fr) | Procede de préparation de méthoxyboranes et de production de methanol | |
| EP3227259A1 (fr) | Synthese d'esters par fonctionnalisation du co2 | |
| JP6707668B2 (ja) | カチオン性ケイ素(ii)化合物およびその製造方法 | |
| FR2975395A1 (fr) | Procede de preparation de composes formamides | |
| WO2021064205A1 (fr) | Procede de preparation d'alcenylaminoboranes et de leurs derives, et leurs utilisations | |
| FR2973371A1 (fr) | Procede de preparation de composes formamides | |
| EP0253700A1 (fr) | Procédé d'hydrogénation asymétrique de composés carbonylés et composés obtenus | |
| JP2963985B2 (ja) | 2−シリルアルケニルボラン化合物およびその製造方法 | |
| EP3194332A1 (fr) | Procede de production de dihydrogene | |
| Zhang | Synthesis of chiral ferrosalen ligands and their applications in asymmetric catalysis | |
| FR2734823A1 (fr) | Nouveaux complexes metalliques optiquement actifs et leur utilisation en catalyse asymetrique | |
| JPH08319246A (ja) | 光学活性なビニルアルコールの製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180920 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200424 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 211/48 20060101ALI20210924BHEP Ipc: C07D 217/04 20060101ALI20210924BHEP Ipc: C07C 209/68 20060101AFI20210924BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20211014 |
|
| INTG | Intention to grant announced |
Effective date: 20211027 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20220308 |